Solid Malignancies Clinical Trial
Official title:
An Open-Label, Phase 1 Trial to Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
Verified date | November 2023 |
Source | Zai Lab (Hong Kong), Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical trial is to test in Chinese Subjects with Metastatic or Recurrent Solid Malignancies. The main questions it aims to answer are: - How is the PK of tisotumab vedotin? - How is the immunogenicity of tisotumab vedotin? - How is the safety and tolerability of tisotumab vedotin? - How is the clinical efficacy of tisotumab vedotin? Participants will receive 2.0 mg/kg tisotumab vedotin (up to a maximum of 200 mg in subjects ≥ 100 kg) as a 30-minute IV infusion 1Q3W with the aim to characterize the PK profiles and to evaluate immunogenicity, safety, and tolerability of tisotumab vedotin in the Chinese population. Subjects will receive study treatment until disease progression or any other discontinuation criteria are met, whichever occurs first. Subjects will undergo an end of treatment (EOT) visit 30 days (± 5 days) after the last dose of study treatment or within 7 days after treatment discontinuation has been decided, whichever occurs later.
Status | Completed |
Enrollment | 19 |
Est. completion date | November 2, 2023 |
Est. primary completion date | November 2, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age =18 years. 2. Must sign an informed consent form (ICF) . 3. Must have recurrent or metastatic solid tumors and have failed on previous standard systemic therapy. 4. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 5. Has life expectancy of at least 3 months. 6. Must demonstrate acceptable screening laboratory values. 7. Female subjects must agree not to breastfeed or donate ova. A male subject who is sexually active with a female partner of reproductive potential and has not had a vasectomy must agree to use a barrier method of birth control (eg, condom with spermicide), and all men must also not donate sperm during the trial and for 6 months after receiving the last dose of tisotumab vedotin. 8. Any other toxicity caused by previous treatment should have recovered to = CTCAE grade 1 or baseline level, except = CTCAE grade 2 alopecia. Exclusion Criteria: 1. Has clinically significant bleeding issues or risks: 2. Has cardiovascular issues or risks: 3. Central nervous system (CNS): any history of intracerebral arteriovenous malformation, cerebral aneurysm, or stroke (transient ischemic attack > 1 month prior to screening is allowed). 4. Ophthalmological: active ocular surface disease or a history of cicatricial conjunctivitis or inflammatory conditions that predispose to cicatrizing conjunctivitis (eg, Wagner syndrome, atopic keratoconjunctivitis, autoimmune disease affecting the eyes), and subjects with penetrating ocular transplants are ineligible. Cataracts alone is not an exclusion criterion. 5. Surgery/procedures: major surgery within 4 weeks or minor surgery within 7 days prior to the first study treatment administration. 6. Peripheral neuropathy = grade 2. 7. Any prior treatment with MMAE-derived drugs. 8. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (dose exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of tisotumab vedotin. 9. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments. |
Country | Name | City | State |
---|---|---|---|
China | Jinan Central Hospital | Jinan | Shangdong |
Lead Sponsor | Collaborator |
---|---|
Zai Lab (Shanghai) Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Objective response rate (ORR) of tisotumab vedotin. | Confirmed objective response rate (ORR) assessed by the investigator per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. | Through study completion, an average of 1 year. | |
Primary | PK parameter AUC of tisotumab vedotin | To assess PK of tisotumab vedotin.PK parameters to be estimated will include area under the concentration-time curve (AUC). | At the end of Cycle 3 (each cycle is 21 days) of the last ongoing patient, about 1 year. | |
Primary | PK parameter Cmax of tisotumab vedotin | To assess PK of tisotumab vedotin.PK parameters to be estimated will include maximum concentration (Cmax). | At the end of Cycle 3 (each cycle is 21 days) of the last ongoing patient, about 1 year. | |
Primary | PK parameter Tmax of tisotumab vedotin | To assess PK of tisotumab vedotin.PK parameters to be estimated will include time to maximum concentration (Tmax). | At the end of Cycle 3 (each cycle is 21 days) of the last ongoing patient, about 1 year. | |
Primary | PK parameter t 1/2 of tisotumab vedotin | To assess PK of tisotumab vedotin.PK parameters to be estimated will include apparent terminal half-life (t 1/2). | At the end of Cycle 3 (each cycle is 21 days) of the last ongoing patient, about 1 year. | |
Primary | PK parameter C trough of tisotumab vedotin | To assess PK of tisotumab vedotin.PK parameters to be estimated will include trough concentration (C trough). | At the end of Cycle 3 (each cycle is 21 days) of the last ongoing patient, about 1 year. | |
Secondary | Immunogenicity of tisotumab vedotin. | Anti-drug antibodies (ADAs) against tisotumab vedotin. | At the end of Cycle 3 (each cycle is 21 days) of the last ongoing patient, about 1 year. | |
Secondary | Treatment-emergent adverse events (TEAEs) of tisotumab vedotin. | A TEAE is defined as a newly occurring or worsening AE from the first dose of study treatment to 30 days after the last dose of study treatment or initiation of new antitumor activities, whichever occurs first. | Through study completion, an average of 1 year. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01202370 -
A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies
|
Phase 1 | |
Completed |
NCT00162136 -
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
|
Phase 1 | |
Recruiting |
NCT05006794 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT02537418 -
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
|
Phase 1 | |
Completed |
NCT01540526 -
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
|
Phase 1 | |
Completed |
NCT00033202 -
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor
|
Phase 1 | |
Recruiting |
NCT04492735 -
The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
|
||
Completed |
NCT02640755 -
Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
|
Phase 1 | |
Terminated |
NCT00695370 -
Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children
|
Phase 2 | |
Completed |
NCT02325739 -
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
|
Phase 1/Phase 2 | |
Completed |
NCT00676299 -
A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.
|
Phase 1 | |
Active, not recruiting |
NCT00090727 -
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
|
Phase 1 | |
Terminated |
NCT01112397 -
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
|
Phase 1 | |
Not yet recruiting |
NCT00751894 -
Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)
|
Phase 2 |